Education
About Us
Working with TipRanks
Follow Us
United Therapeutics (UTHR)
NASDAQ:UTHR
Earnings Data
Report Date
Apr 30, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
6.54Last Year’s EPS
6.17Same Quarter Last Year
Moderate Buy
Based on 11 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Feb 26, 2025
|% Change Since: -10.48%
|Next Earnings Date:Apr 30, 2025
Earnings Call Sentiment|Positive
The earnings call highlighted United Therapeutics' record-breaking revenue and strong growth across major product lines. The company is progressing well with its innovative clinical trials and strategic capital allocation, despite a slight sequential decline in net revenue for Q4 due to contracting adjustments. The sentiment is largely positive, focusing on future growth and advancements.Company Guidance
During the United Therapeutics Corporation Fourth Quarter 2024 earnings call, the company reported another record year with approximately 24% revenue growth over 2023, driven by double-digit percent revenue growth in major contributors like Tyvaso, U.S. Remodulin, Orenitram, and Unituxin. The company achieved 20% revenue growth for the quarter compared to the fourth quarter of 2023. Tyvaso revenue for Q4 was $4 million, marking a 19% increase over the previous year. The company also highlighted the commencement of a three-year cascade of clinical and regulatory events, including the uKidney clinical trial and the inhaled treprostinil Teton studies. The uKidney trial, cleared by the FDA, aims to address the needs of end-stage renal disease patients. Additionally, United Therapeutics emphasized its capital allocation strategy, having returned $1 billion to shareholders through an accelerated share repurchase program. The company aims to maintain double-digit revenue growth through the mid-2020s, with potential inflections upon the expected approvals of Ralinepag and inhaled treprostinil for idiopathic pulmonary fibrosis (IPF).Record Revenue for 2024
United Therapeutics achieved record revenue for the third consecutive year, driven by double-digit growth across major products like Tyvaso, Remodulin, Orenitram, and Unituxin, leading to nearly 24% growth over 2023.
Significant Progress in Clinical Trials
The company began a three-year cascade of clinical and regulatory events, including FDA clearance for the uKidney xenotransplant trial and progress in the Teton 1 and 2 studies for inhaled treprostinil.
Ralinepag Development
Advancements with Ralinepag, a potential first true once-a-day oral prostacyclin agonist for PAH, which could change treatment paradigms.
Strong Performance Across Products
Tyvaso revenue increased 19% YoY for Q4, Orenitram grew 28%, Remodulin grew 17%, and Unituxin revenue increased by 25%.
Successful Capital Allocation
United Therapeutics returned $1 billion to shareholders through an accelerated share repurchase program and invested in infrastructure and acquisitions to support future growth.
---
UTHR Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
UTHR Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Feb 26, 2025 | $357.50 | $318.89 | -10.80% |
| Oct 30, 2024 | $352.80 | $361.40 | +2.44% |
| Jul 31, 2024 | $337.54 | $313.29 | -7.18% |
| May 01, 2024 | $234.33 | $255.14 | +8.88% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does United Therapeutics (UTHR) report earnings?
United Therapeutics (UTHR) is schdueled to report earning on Apr 30, 2025, TBA Not Confirmed.
What is United Therapeutics (UTHR) earnings time?
United Therapeutics (UTHR) earnings time is at Apr 30, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is UTHR EPS forecast?
UTHR EPS forecast for the fiscal quarter 2025 (Q1) is 6.54.
---